SCHEMBL20738593

SCHEMBL20738593

CC(=O)N1CC2CC(C1)c1ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
NOTUM Q6P988 3/20 0.47
CHRNA3 P32297 4/20 0.44
CHRNB2 P17787 3/20 0.44
CHRNA4 P43681 3/20 0.44
CHRNB3 Q05901 1/20 0.44
CHRNA6 Q15825 1/20 0.44
ALDH1A1 P00352 2/20 0.41
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
CHRNB4 P30926 3/20 0.41
CHRNA7 P36544 1/20 0.40
KIF11 P52732 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25951598 0.80 CHRNB2 (0.50) KMT2AMEN1CHRNA3CHRNB2CHRNA4
SCHEMBL1790866 0.78 POLB (0.52) KMT2AMEN1NOTUMALDH1A1POLB
SCHEMBL1971200 0.77 RBP4 (0.43) CYP3A4CYP2C9CYP2C19EPHX2
SCHEMBL13916013 0.77 RBP4 (0.43) CYP3A4CYP2C9CYP2C19EPHX2
SCHEMBL25951586 0.75 CHRNB4 (0.57) CHRNA3ALDH1A1POLBKDM4ECHRNB4
SCHEMBL11540652 0.73 MEN1 (0.52) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL14524430 0.73 ALDH1A1 (0.42) KMT2AMEN1CHRNA3CHRNB2CHRNA4
SCHEMBL13369611 0.73 CHRNB4 (0.48) CHRNA3CHRNB2CHRNA4KDM4EBRD4
SCHEMBL21787691 0.73 CHRNB4 (0.48) CHRNA3CHRNB2CHRNA4KDM4EBRD4
SCHEMBL13807402 0.73 CHRNB4 (0.48) CHRNA3CHRNB2CHRNA4KDM4EBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 KMT2A 968/4885MEN1 1644/4885NOTUM 4102/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 KMT2A 968/4885MEN1 1644/4885NOTUM 4102/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 KMT2A 997/4885MEN1 1766/4885NOTUM 4156/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 KMT2A 968/4885MEN1 1644/4885NOTUM 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.